Case Studies

Institute of Cardiovascular Science - University College London

In 2007 we were engaged by UCL Partners (UCL, Great Ormond Street and University College Hospital NHS Trust) to put together a business plan for, and provide support for the establishment of, a new translational Institute of Cardiovascular Science. The Institute is now developing a coherent disease focused research strategy (around earlier identification, prevention and treatment of cardiovascular risk), drawing on disciplines across the whole UCL campus. Structured as a Joint Venture between the Partners, the Institute is intended to be the vehicle through which industry, research charities and patient groups can shape and support cutting edge experimental medicine."

"The 4D Biomedical team brought great professionalism to our project. Their advice was invaluable".

Professor Andrew Copp MBBS DPhil FRCPath FMedSci
Director, UCL Institute of Child Health
Non-Executive Director, Great Ormond Street Hospital.

Leeds Institute of Genetics and Therapeutics

Following an introduction by one of the UK's leading research charities, we were approached and engaged to prepare a translational research strategy and IPR exploitation model for a major NHS Trust and University in a major urban conurbation. Building on the existing facilities and research in place, we developed a model for accelerating the integration of clinical and academic science through a major new Joint Venture between the Trust and University.

‘The team at 4D have the expertise and understanding to skilfully cover the gap that currently exists between academia and commercialisation. Approachable, informed and able to perform swift analysis of problems and potential solutions relevant to this difficult area. Tremendously valuable partners to help guide you through the commercialisation processes’

Peter J Grant
Professor of Medicine
Honorary Consultant Physician
Head, Division of Cardiovascular & Diabetes Research
The LIGHT Laboratories, Clarendon Way

GENESERVICE

4D was engaged by the management of Geneservice to help with the planning and preparation of their successful acquisition in 2007. We provided a combination of market intelligence and analysis on key trends in the pharmacogenomics sector and their potential acquirors, and hands-on support with the preparation of the business case.

"The 4D team provided invaluable, practical transaction support in our successful bid to be acquired. Their combination of industry and finance expertise, hands-on approach and understanding of how deals work was invaluable. "

Tom Weaver

Former CEO, Geneservice

Translational medicine collaboration

In summer 2005 we were retained by Scottish Enterprise to conduct research into the market for biomarker collaborations around the world, and to advise on the most appropriate commercialisation model for a Scottish consortium. Following that project, we were retained to advise the consortium of NHS Trusts, four universities and Scottish Enterprise on the transaction with Wyeth Pharmaceuticals including:

Developing a business model for the collaboration, including novel mechanisms for licensing of biomarker IP
Tracking comparator deals - both biomarker licensing and public health collaborations - around the world
Preparing robust intellectual property licensing revenue forecasts
Supporting the negotiation of IP and Collaboration Agreement
Preparing financial cost and revenue models

The collaboration will see $50m of research spend in a large range of programmes across five major therapeutic areas. Based around the Clinical Research Network developed by the Scottish NHS, the collaboration has at its core a multi-disciplinary programme of candidate drug interrogation.

The deal was completed in April 2006. Contact us for further details.

Translational Medicine Research Collaboration is awarded “Best Investment in Europe”

Wyeth Pharmaceuticals has been awarded one of three 'Best Investment in Europe' titles at the La Baule World Investment Conference for its role in creating the world's first Translational Medicine Research Collaboration (TMRC) in Scotland in 2006.

The 4D Biomedical team advised Scottish Enterprise on the collaboration.

Wyeth Pharmaceuticals, with headquarters in Collegeville, Pennsylvania, plans to invest an estimated £33m in the collaboration in its first five years, with an option to extend for a further five years. Scottish Enterprise will invest up to £17.5m.

The £50 million collaboration comprises four of Scotland's leading universities (Aberdeen, Dundee, Edinburgh and Glasgow), Wyeth Pharmaceuticals, Scottish Enterprise and NHS Scotland Grampian, Greater Glasgow, Lothian and Tayside, and will provide new impetus for Scotland to lead the world in the development of personalised medicine, bringing new treatments to patients suffering from a range of serious illnesses.

TMRC has already invested almost £8 million of funding to support 28 new research projects covering a wide range of therapeutic areas including cardiovascular and metabolic disease, the central nervous system, oncology, inflammation, and women's health.

As a result, over 40 new jobs have already been created with a further 50 projected for the project’s Core Laboratory in Dundee.